Primo Biotechnology is at the forefront of precision medicine, particularly in the field of radiopharmaceuticals for cancer diagnosis and treatment. The company specializes in molecular image-guided and targeted therapies, utilizing advanced radioligand theranostics (RLT) to enhance the accuracy of cancer diagnostics and improve therapeutic outcomes. Their innovative approach includes the development of novel radiopharmaceuticals and manufacturing processes, supported by a team of professionals with extensive experience in clinical investigations and regulatory applications. Notably, Primo's recent collaborations, such as the FDA-approved Phase I/II trial of AS1986NS, highlight their commitment to advancing precision oncology through real-time imaging technologies that improve biopsy accuracy.

In addition to their clinical advancements, Primo Biotechnology offers a comprehensive platform for pre-clinical research, which includes specialized animal models and in-vivo imaging techniques. Their pre-clinical services utilize various models, such as allogeneic and xenograft models, to evaluate tumor metabolism and treatment efficacy. The integration of modern organoid models and high-throughput screening (HTS) technologies further enhances their research capabilities, allowing for more efficient drug development and personalized treatment strategies. By combining their expertise in radiopharmaceuticals with cutting-edge pre-clinical methodologies, Primo aims to significantly impact cancer care and expand its influence in the global market.

Taiwan

Primo is a radiopharmaceutical company based in Taiwan. In order to facilitate precision healthcare with molecular imaging in Taiwan, Primo was founded by Prof. Ya-Yao Huang and Dr. Joe Yeh in 2021 with many-year radiopharmaceutical discovery/development experience in Taiwan, especially about clinical introduction and IND submission of new radiopharmaceuticals.

For several years now, our company has been focused on the one-stop clinical development of radiotheranostics in Taiwan, especially form pre-clinical studies, clinical network and regulatory filling to manufacturing , commercialization and distribution activities in Taiwan.

Primo Biotechnology

Company Details